



NDA 17-058/S-017

Roxane Laboratories, Inc.
P.O. Box 16532
Columbus, OH 43216-6532

Attention: Robert Pfeifer, R.Ph., M.S.
Associate Director, Medical Services
Drug Regulatory Affairs, Approved Products

Dear Mr. Pfeifer:

Please refer to your supplemental new drug application dated November 9, 2006, received November 13, 2006, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for DISKETTS Dispersible Tablets (methadone HCl).

This supplemental new drug application was submitted in response to the Agency's letter dated October 17, 2006, requesting extensive changes to the Package Insert for DISKETTS.

We have completed our review of this application, and it is approved effective on the date of this letter for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the enclosed labeling text for the package insert and patient package insert.

Within 21 days of the date of this letter, submit content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format, as described at <http://www.fda.gov/oc/datacouncil/spl.html>, that is identical in content to the enclosed labeling text. Upon receipt and verification, we will transmit that version to the National Library of Medicine for public dissemination.

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH
Food and Drug Administration
5515 Security Lane
HFD-001, Suite 5100
Rockville, MD 20852

NDA 17-058/S-017

Page 2

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Matt Sullivan, Regulatory Project Manager, at 301-796-1245.

Sincerely,

{See appended electronic signature page}

Bob Rappaport, M.D.
Director
Division of Anesthesia, Analgesia
and Rheumatology Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

Enclosure

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Bob Rappaport
12/7/2006 03:27:56 PM